<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immuneonco Biopharmaceuticals (shanghai) Inc Class H — News on 6ix</title>
<link>https://6ix.com/company/immuneonco-biopharms</link>
<description>Latest news and press releases for Immuneonco Biopharmaceuticals (shanghai) Inc Class H on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 13 Nov 2025 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immuneonco-biopharms" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683686e378dffbe2df16aa8c.webp</url>
<title>Immuneonco Biopharmaceuticals (shanghai) Inc Class H</title>
<link>https://6ix.com/company/immuneonco-biopharms</link>
</image>
<item>
<title>Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumorsDALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update.Recent Highlights:In September, ImmuneOnco, Instil’s collaborator, presented updated data f</description>
</item>
<item>
<title>Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/instil-bio-announces-immuneoncos-presentation-of-2510-monotherapy-data-in-patients-with-2l-squamous-nsclc-at-the-2025-world-conference-on-lung-cancer-wclc</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/instil-bio-announces-immuneoncos-presentation-of-2510-monotherapy-data-in-patients-with-2l-squamous-nsclc-at-the-2025-world-conference-on-lung-cancer-wclc</guid>
<pubDate>Wed, 10 Sep 2025 11:00:00 GMT</pubDate>
<description>ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK)</description>
</item>
<item>
<title>Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/instil-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/instil-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 13 Aug 2025 10:00:00 GMT</pubDate>
<description>With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financi</description>
</item>
<item>
<title>ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/immuneonco-announced-preliminary-safety-and-efficacy-data-from-the-clinical-trial-studying-imm2510axn-2510-a-pd-l1xvegf-bispecific-antibody-in-combination-with-chemotherapy-in-front-line-nsclc-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/immuneonco-announced-preliminary-safety-and-efficacy-data-from-the-clinical-trial-studying-imm2510axn-2510-a-pd-l1xvegf-bispecific-antibody-in-combination-with-chemotherapy-in-front-line-nsclc-in-china</guid>
<pubDate>Thu, 31 Jul 2025 10:00:00 GMT</pubDate>
<description>Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC ImmuneOnco expects to present updated safety and efficacy data at a future medical conference DALLAS and SHANGHAI, July 31, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) noted that ImmuneOnco Biopharmaceuticals (Shanghai) Inc</description>
</item>
<item>
<title>Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/instil-bio-announces-us-fda-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsedrefractory-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/instil-bio-announces-us-fda-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsedrefractory-solid-tumors</guid>
<pubDate>Wed, 02 Jul 2025 10:00:00 GMT</pubDate>
<description>US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (“’2510”)</description>
</item>
<item>
<title>Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/instil-bio-and-immuneonco-to-host-investor-and-analyst-breakfast-to-discuss-the-evolving-pd-l1xvegf-bispecific-antibody-landscape-and-clinical-trial-updates-during-the-2025-asco-annual-meeting-in-chicago</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/instil-bio-and-immuneonco-to-host-investor-and-analyst-breakfast-to-discuss-the-evolving-pd-l1xvegf-bispecific-antibody-landscape-and-clinical-trial-updates-during-the-2025-asco-annual-meeting-in-chicago</guid>
<pubDate>Fri, 23 May 2025 11:00:00 GMT</pubDate>
<description>DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center. Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the ev</description>
</item>
<item>
<title>Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025</title>
<link>https://6ix.com/company/immuneonco-biopharms/news/instil-bio-and-immuneonco-announced-the-phase-2-trial-in-first-line-nsclc-of-imm2510axn-2510-2510-a-pd-l1xvegf-bispecific-antibody-in-combination-with-chemotherapy-in-china-is-on-track-to-complete-enrollment-in-q3-2025-initial-results-anticipated-in-2h-2025</link>
<guid isPermaLink="true">https://6ix.com/company/immuneonco-biopharms/news/instil-bio-and-immuneonco-announced-the-phase-2-trial-in-first-line-nsclc-of-imm2510axn-2510-2510-a-pd-l1xvegf-bispecific-antibody-in-combination-with-chemotherapy-in-china-is-on-track-to-complete-enrollment-in-q3-2025-initial-results-anticipated-in-2h-2025</guid>
<pubDate>Thu, 22 May 2025 10:00:00 GMT</pubDate>
<description>Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions Monotherapy US dose optimization Phase 1b/2 trial of ‘2510 in relapsed/refractory solid tumors, intended to bridge the doses to the ongoing China trials, replaces the previously planned US trial DALLAS and SHANGHAI, May 22, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX C</description>
</item>
</channel>
</rss>